公开(公告)号：EP1879896A1

公开(公告)日：2008-01-23

申请号：EP06740278.4

申请日：2006-04-03

申请人： ELI LILLY AND COMPANY

发明人： COLLINS, Elizabeth, Aaron ,  GARCIA-LOSADA, Pablo ,  HAMDOUCHI, Chafiq ,  HIPSKIND, Philip, Arthur ,  LU, Jianliang ,  TAKAKUWA, Takako

IPC分类号： C07D487/04 ,  A61K31/5025 ,  A61P25/20

CPC分类号： C07D487/04

摘要： The present invention relates to novel substituted imidazo[1,2-b] pyridazine compounds of Formula (I) pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.

摘要翻译： 本发明涉及式（I）的新型取代的咪唑并[1,2-b]哒嗪化合物及其药物组合物，以及该化合物如促肾上腺皮质激素释放因子1（CRF1）受体拮抗剂在治疗精神病和神经疾病中的用途 。

公开(公告)号：EP1869049B1

公开(公告)日：2009-03-04

申请号：EP06738924.7

申请日：2006-03-20

申请人： ELI LILLY AND COMPANY

发明人： BARBOSA, Heather, Janelle ,  COLLINS, Elizabeth, Aaron ,  HAMDOUCHI, Chafiq ,  HEMBRE, Erik, James ,  HIPSKIND, Philip, Arthur ,  JOHNSTON, Richard, Duane ,  LU, Jianliang ,  RUPP, Michael, John ,  TAKAKUWA, Takako ,  THOMPSON, Richard, Craig

IPC分类号： C07D487/04 ,  A61K31/5025 ,  A61P25/20

CPC分类号： C07D487/04

摘要： The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I): pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.

公开(公告)号：EP1869049A1

公开(公告)日：2007-12-26

申请号：EP06738924.7

申请日：2006-03-20

申请人： ELI LILLY AND COMPANY

发明人： BARBOSA, Heather, Janelle ,  COLLINS, Elizabeth, Aaron ,  HAMDOUCHI, Chafiq ,  HEMBRE, Erik, James ,  HIPSKIND, Philip, Arthur ,  JOHNSTON, Richard, Duane ,  LU, Jianliang ,  RUPP, Michael, John ,  TAKAKUWA, Takako ,  THOMPSON, Richard, Craig

IPC分类号： C07D487/04 ,  A61K31/5025 ,  A61P25/20

CPC分类号： C07D487/04

摘要： The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I): pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.